Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
Melissa L. Johnson, Byoung Chul Cho, Alexander Luft, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 6, pp. 1213-1227
Open Access | Times Cited: 252

Showing 1-25 of 252 citing articles:

Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 449
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lizza E.L. Hendriks, Keith M. Kerr, Jessica Menis, et al.
Annals of Oncology (2023) Vol. 34, Iss. 4, pp. 358-376
Open Access | Times Cited: 319
Tremelimumab: First Approval
Susan J. Keam
Drugs (2022) Vol. 83, Iss. 1, pp. 93-102
Open Access | Times Cited: 72
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Ana Pilar González-Rodríguez, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2912-2912
Open Access | Times Cited: 68
Immunosurveillance in clinical cancer management
Guido Kroemer, Timothy A. Chan, Alexander M.M. Eggermont, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 74, Iss. 2, pp. 187-202
Open Access | Times Cited: 62
Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks
Lingjiao Meng, Haotian Wu, Jiaxiang Wu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 57
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 6, pp. 755-768
Open Access | Times Cited: 47
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
Yuanyuan Zhao, Gang Chen, Jianhua Chen, et al.
EClinicalMedicine (2023) Vol. 62, pp. 102106-102106
Open Access | Times Cited: 42
New promises and challenges in the treatment of advanced non-small-cell lung cancer
May-Lucie Meyer, Bailey G Fitzgerald, Luís Paz-Ares, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 803-822
Closed Access | Times Cited: 38
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives
Xiaoli Shi, Xinyi Wang, Wentao Yao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 30
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Martin Schüler, Kristof Cuppens, Till Plönes, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1602-1611
Open Access | Times Cited: 29
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3
Ishmael Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. e23-e43
Closed Access | Times Cited: 25
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Xueqing Kong, Jinyi Zhang, Shuwei Chen, et al.
Cancer Biology and Medicine (2024), pp. 1-11
Open Access | Times Cited: 20
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
Joel W. Neal, Nick Pavlakis, Sang‐We Kim, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 20, pp. 2393-2403
Open Access | Times Cited: 17
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Gilberto de Castro, Naiyer A. Rizvi, Peter Schmid, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 1, pp. 106-119
Open Access | Times Cited: 44
Immunotherapy-based combinations in metastatic NSCLC
Aakash Desai, Solange Peters
Cancer Treatment Reviews (2023) Vol. 116, pp. 102545-102545
Open Access | Times Cited: 36
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1
Navneet Singh, Ishmael Jaiyesimi, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. e51-e62
Closed Access | Times Cited: 30
Fcγ receptors and immunomodulatory antibodies in cancer
Felipe Gálvez‐Cancino, Alexander P. Simpson, Cristóbal Costoya, et al.
Nature reviews. Cancer (2023) Vol. 24, Iss. 1, pp. 51-71
Closed Access | Times Cited: 29
Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers
Satoshi Muto, Akio Enta, Yoshiyuki Maruya, et al.
Biomedicines (2023) Vol. 11, Iss. 1, pp. 190-190
Open Access | Times Cited: 28
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
Harriet M. Kluger, J. Carl Barrett, Justin F. Gainor, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e005921-e005921
Open Access | Times Cited: 28
Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
Dorine de Jong, Jeeban P. Das, Hong Ma, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2855-2855
Open Access | Times Cited: 27
Current Status in Rechallenge of Immunotherapy
Han Hu, Ke Wang, Rong Jia, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 8, pp. 2428-2442
Open Access | Times Cited: 23
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
Caicun Zhou, Yanping Hu, Ekaterine Arkania, et al.
Cancer Cell (2024) Vol. 42, Iss. 2, pp. 198-208.e3
Closed Access | Times Cited: 15
KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial
Yuanyuan Zhao, Gang Chen, Xingya Li, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101470-101470
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top